SHL Telemedicine Ltd

SHLTN

Equity

ISIN IL0010855885 / Valor 1128957

SIX Swiss Exchange (2024-09-18)

CHF 3.09+8.42%

SHL Telemedicine Ltd
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

SHL Telemedicine Ltd specializes in the development and provision of advanced telemedicine solutions and services, focusing on the diagnosis and monitoring of heart conditions and various chronic diseases. The company is recognized as a leading provider of telemedicine in Israel and Germany, offering 24/7 telemedicine centers in these countries, with services extending globally through cloud technology. SHL Telemedicine facilitates around 3 million medical interactions annually and is noted for its innovation in personal use hospital-grade mobile 12-lead ECG devices, which have received FDA clearance. The company's product portfolio includes a range of telemedicine devices designed for personal use, enabling real-time transmission of critical medical data, such as ECG and blood pressure readings, to SHL's medical monitoring centers for immediate evaluation. SHL Telemedicine's operations leverage artificial intelligence and big data technologies, and the company collaborates with leading healthcare industry partners, including the Mayo Clinic, to enhance its service offerings and expand its market presence, particularly in Germany and the USA.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

SHL Telemedicine Ltd. reported revenues of USD 29.0 million for the first half of 2023, showing a slight increase compared to USD 28.8 million in the first half of 2022 when adjusted for constant currency. This growth reflects the company's stable performance amidst challenging market conditions.

Adjusted EBITDA

For the first half of 2023, SHL Telemedicine Ltd.'s adjusted EBITDA was USD 0.4 million, a decrease from USD 3.1 million in the same period of 2022 when adjusted for constant currency. The decline is attributed to increased investments in Germany and the USA, as well as expenses related to the Nasdaq listing.

Net Loss

SHL Telemedicine Ltd. reported a net loss of USD 2.1 million for the first half of 2023, compared to a small net loss of USD 0.1 million in the first half of 2022 when adjusted for constant currency. The increased net loss is primarily due to higher investments and operational costs.

Germany Operations

In Germany, SHL Telemedicine Ltd. generated revenues of USD 6.8 million in the first half of 2023, slightly down from USD 7.0 million in the same period of 2022 when adjusted for constant currency. The company has started the commercial service of Virtual Visits to BARMER insureds, covering over 12.5 million insureds in Germany.

Israel Operations

Revenues in Israel increased by 3% to USD 21.6 million in the first half of 2023, compared to USD 21.0 million in the same period of 2022 when adjusted for constant currency. SHL Telemedicine Ltd. is expanding its B2C and B2B operations and expects to introduce new products and services in Israel within the year.

Summarized from source with an LLMView Source

Key figures

-65.3%1Y

-80.6%3Y

-47.6%5Y

Performance

75.0%1Y

60.2%3Y

60.5%5Y

Volatility